SAR 118 promising for dry eye


Data show rapid increase in tear production along with improved staining and symptoms

Results of a phase II study indicate that a novel smallmolecule integrin antagonist is a promising anti-inflammatory treatment for dry eye, said researchers at the annual meeting of the Association for Research in Vision and Ophthalmology.

The phase II study evaluating SAR 1118 was a multicentre, double-masked, placebo-controlled trial that enrolled 230 adults with bilateral keratoconjunctivitis sicca (KCS). Eligible patients had to have a Schirmer tear test (STT) result of >1 to <10 mm/5 min, no active lid margin disease, and a response with exacerbation of fluorescein corneal staining and ocular symptoms during screening using the Controlled Adverse Environment (Ora Inc.). Prior treatment with topical cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan) was allowed, but had to be discontinued for at least 6 weeks.

Inferior fluorescein corneal staining score at week 12 in the intenttotreat population was the pre-specified primary efficacy endpoint, and the results showed a dose-response effect and strong statistical trend in favor of SAR 1118. Mean reduction from baseline staining was 75% for patients treated with SAR 1% and 88% in the SAR 5% group. Doseresponse effects were also seen in analyses of STT data and Ocular Surface Disease Index (OSDI) scores. Already by the first follow-up visit at 2 weeks after random assignment, patients treated with SAR 1118 5% had a statistically significant improvement in the STT (p = 0.0392) with further improvement at 12 weeks, although the latter benefit only showed a trend to statistical significance (p = 0.0905) because STT also increased in the placebo group.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Related Content
© 2023 MJH Life Sciences

All rights reserved.